

July 7, 2022

Via EDGAR

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549

Attn: Ada D. Sarmiento

**Re: Calliditas Therapeutics AB**  
**Registration Statement on Form F-3**  
**Filed June 28, 2022**  
**File No. 333-265881**

Acceleration Request

Requested Date: July 8, 2022

Requested Time: 4:00 p.m. Eastern Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the "**Registrant**") hereby requests that the Securities and Exchange Commission (the "**Commission**") take appropriate action to cause the above-referenced Registration Statement on Form F-3 (File No. 333-265881) (the "**Registration Statement**"), to become effective on July 8, 2022, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the Commission's staff. The Registrant hereby authorizes Joshua Kaufman of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Joshua Kaufman of Cooley LLP at (212) 479-6495.

*[Signature page follows]*

---

Very truly yours,

Calliditas Therapeutics AB

By: /s/ Renée Aguiar-Lucander  
Renée Aguiar-Lucander  
*Chief Executive Officer*

---

cc:

Fredrik Johansson, Calliditas Therapeutics AB  
Jonathan Schur, Calliditas Therapeutics AB  
Josh Kaufman, Cooley LLP  
Katie Kazem, Cooley LLP  
Dain Hard Nevonon, Advokatfirman Vinge KB  
Linnea Sellström, Advokatfirman Vinge KB

---